Navigation Links
American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
Date:10/18/2007

d by researchers at Reproductive Medicine Associates of New Jersey (RMANJ).

"Accurate and rapid identification of chromosomally-abnormal (aneuploid) embryos within hours after embryo biopsy will provide physicians with the ability to select embryos for transfer to the uterus based on a far more complete and accurate picture of their genetic health than has ever been possible," said Nathan Treff, Ph.D., researcher at RMANJ and principal investigator and lead author of the study. "This could, in turn, allow us to reduce the number of embryos implanted while increasing the chances that couples treated with IVF will have a healthy baby."

Currently, the most commonly used technology for chromosomal analysis of embryos (sometimes termed preimplantation genetic diagnosis or PGD), is florescent in situ hybridization (FISH). This technique assesses fewer than half of the 23 chromosome pairs found in the human karyotype and has a suboptimal error rate. This makes it possible for many genetic abnormalities to go undetected. Prior technologies that have attempted to analyze all 23 chromosome pairs have not been useful because of the length of time required to provide accurate results.

"To improve safety and success in IVF, we must improve our ability to screen embryos. That's why this research is so important and why we must support every effort to make this new technology available to patients," Ms. Madsen added.

In this new process, a single cell is removed from an embryo and the genetic code for that cell is copied up to a million times. Once amplified, approximately 250,000 different areas of the DNA, called single nucleotide polymorphisms (SNPs, or "snips"), are individually examined. This process makes it possible to identify any deviations from the normal genetic copy. This information can, in turn, help doctors to identify embryos that offer the highest chances of successful implantation, healthy pregnancy, and a healthy baby.

About the AFA
'/>"/>

SOURCE American Fertility Association
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
10. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...karia Holdings, Inc. today announced that it has b...ersey Technology Council (NJTC), a 1,200-member no...rt, networking opportunities, information and advo...karia earned the award based on criteria including...ision. , , "We are delighted that the New J...
(Date:11/20/2008)...T PHASE III TRIAL SHOW SIGNIFICANT, DECREASES...CTION, IN, FIBROMYALGI... Belgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz ...uronext Brussels: UCB),announced today positive p...,Phase III pivotal clinical trials of sodium oxyba...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 1Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 2Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 3Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 4Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 5Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 6Regular tipple may curb risk of rheumatoid arthritis 21104 1Regular tipple may curb risk of rheumatoid arthritis 21104 2Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 1Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 1MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 3
..., Germany, May 31, 2007- Results from various,clin...n patients,with advanced hepatocellular carcinoma,...tablets will be presented at the Annual,Meeting of...in,Chicago, USA from June 1 - 5, 2007. , On this o...ts,will be held on June 4, 2007. Starting at aroun...
...f Abstracts Reflects Continued Growth of Eisai,s,C...1, 2007 /PRNewswire/ -- Eisai,announced today that...eir oncology pipeline compounds have been accepted...cal Oncology (ASCO),annual meeting. ASCO takes pla...ts reveal a growing and diverse oncology clinical,...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:11/21/2008)...an, fresh from basic training and now serving over...e life he saved by donating his rare blood type. ...c of Korea (PRWEB) November 21, 2008 -- A local Ko...nation saved her life, met for the first time when... , ,Airman Tamarias Pope, 8th Security Forces Squa...
(Date:11/21/2008)...ork together to stop abusive behavior, experts say... Behavior that was once dismissed as "kids being k...unting research shows the negative effects on both...nals, schools, parents and even kids themselves ar...ng behavior. , "Bullying shouldn,t be consider...
(Date:11/21/2008)...ty of Texas Health Science Center at Houston will ... Studies (TEXAS), to promote geriatrics training f...rd from the Donald W. Reynolds Foundation and $1.2... to teach geriatric medicine principles to everyon...ng physicians. With the reach of Lyndon B. Johnson...
(Date:11/21/2008)...FirstCall/ -- The Providence Service,Corporation ...rris, the Company,s,Chief Operating Officer, has ...s. Mr. Norris, appointment fills the vacancy left...ger and returns the board to six members. Mr.,No... , Mr. Norris, age 41, has been with Provid...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: